TINDAMAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TINDAMAX (TINDAMAX).
Tindamax (tinidazole) is a nitroimidazole antibiotic that enters bacterial and protozoal cells, where the nitro group is reduced by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It exhibits activity against anaerobic bacteria and protozoa.
| Metabolism | Tinidazole is extensively metabolized in the liver via oxidation by CYP450 enzymes (mainly CYP3A4) and glucuronidation. The major metabolite is the hydroxy derivative, which retains some activity. |
| Excretion | Primarily renal excretion (70-80% as unchanged drug) with 10-15% fecal elimination via biliary secretion. |
| Half-life | Terminal elimination half-life is 4-6 hours; prolonged to 10-12 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 45% bound to albumin. |
| Volume of Distribution | 0.5 L/kg; indicates distribution into total body water and moderate tissue penetration. |
| Bioavailability | Oral bioavailability is 90-100% (well absorbed). |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes. |
| Duration of Action | 6-12 hours depending on dose and infection severity; extended to 24 hours in once-daily dosing regimens. |
| Molecular Weight | 425.5 |
100 mg intravenously every 8 hours over 60 minutes.
| Dosage form | TABLET |
| Renal impairment | GFR > 50 mL/min: No adjustment. GFR 30-50 mL/min: 100 mg every 12 hours. GFR < 30 mL/min: 100 mg every 24 hours. Hemodialysis: 100 mg after dialysis on dialysis days. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 100 mg every 12 hours. Child-Pugh C: 100 mg every 24 hours. |
| Pediatric use | 2 mg/kg/dose intravenously every 8 hours; maximum 100 mg per dose. |
| Geriatric use | No specific adjustment beyond renal function; consider decreased renal clearance and monitor for adverse effects. |
| 1st trimester | Avoid. Teratogenic effects observed in animal studies; no adequate human data. |
| 2nd trimester | Avoid. Risk of fetal harm; use only if benefit outweighs risk. |
| 3rd trimester | Avoid. May cause neonatal complications; use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for TINDAMAX (TINDAMAX).
| Placental transfer | Known to cross placenta in humans; detected in fetal plasma at concentrations similar to maternal plasma. |
| Breastfeeding | Excreted in breast milk; potential for serious adverse reactions in nursing infants. Discontinue breastfeeding or discontinue drug. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to TINDAMAXPregnancyLactationSevere hepatic impairment
| Precautions | Carcinogenicity has been observed in animal studies with chronic use; avoid long-term use., Neurologic adverse effects, including peripheral neuropathy and seizures, may occur., Disulfiram-like reaction with alcohol: avoid alcohol during therapy and for 3 days after last dose., May cause metallic taste, nausea, and dizziness. |
| Food/Dietary | Food does not significantly alter absorption but may reduce GI side effects. Avoid alcohol and any alcohol-containing foods, beverages, or medications (e.g., cough syrups, mouthwashes) for the duration of therapy and for 72 hours after the last dose due to risk of disulfiram-like reaction. |
Loading safety data…
| L5 |
| Teratogenic Risk | First trimester: Risk category D. Associated with Ebstein's anomaly and other congenital heart defects. Second/third trimester: Risk category D. May cause fetal nephrotoxicity, oligohydramnios, and cranial ossification delay. Avoid in pregnancy unless no alternative. |
| Fetal Monitoring | Maternal: Serum electrolytes, renal function, hepatic function, complete blood count, and uric acid. Fetal: Ultrasound for fetal anomalies and amniotic fluid index during second/third trimesters. |
| Fertility Effects | May impair fertility in females by disrupting ovulation. In males, reversible oligospermia has been reported. Impact on fertility is generally temporary after discontinuation. |
| Clinical Pearls | TINDAMAX (tinidazole) is a 5-nitroimidazole with a longer half-life than metronidazole, allowing once-daily dosing. It achieves high concentrations in the CNS and genitourinary tract. Monitor for disulfiram-like reactions with alcohol; avoid alcohol during therapy and for 72 hours after last dose. Dose adjustment recommended in severe hepatic impairment (Child-Pugh C). |
| Patient Advice | Take TINDAMAX exactly as prescribed, with food to reduce gastrointestinal upset. · Avoid alcohol and alcohol-containing products during treatment and for 3 days after the last dose to prevent severe nausea, vomiting, and headache. · Complete the full course of therapy even if symptoms improve. · Report any signs of allergic reaction, neuropathy (numbness, tingling), or CNS effects (dizziness, seizures) immediately. · TINDAMAX may cause a metallic taste in the mouth; this is temporary. |